Latest Content

OS Therapies began a rolling submission of a BLA for OST-HER2 in fully resected pulmonary metastatic osteosarcoma.

A real-world cilta-cel study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

EMA CHMP recommends first-line retifanlimab plus carboplatin/paclitaxel for advanced anal cancer, backed by phase 3 P0D1UM-303 data.

With an additional 16.1 months of follow-up, the dual HER2-targeted, chemotherapy-free regimen maintained efficacy and safety in HER2-positive mCRC.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

Part 2 of the ongoing phase 2/3 HARBOR study is evaluating elenestinib in patients with indolent systemic mastocytosis.

Real-world data confirm the importance of tumor debulking with bridging therapy to reduce the risk of parkinsonism and NRM with cilta-cel in myeloma.

Ustekinumab plus prophylaxis did not reduce acute GVHD in patients who underwent HCT from matched unrelated donors.

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Mabel Mardones, MD, discusses implications of data for Dato-DXd and sacituzumab govitecan in frontline metastatic triple-negative breast cancer.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.